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1. Introduction 
Orthotopic liver transplantation (OLT) has become the effective treatment for end-stage liver 
diseases. Since the 1980s, the successful rate of liver transplantation has increased with the 
improvement of operative methods and the use of University of Wisconsin (UW) solution. 
Nevertheless, liver procurement and implantation are inevitably associated with allograft 
damage. Lack of donor liver hinders OLT and leads to an increase in the number of deaths on 
the waiting list and as a consequence the transplant community has greatly expanded the use 
of non-ideal donors to improve the rate of transplant (Delmonico et al., 2005). Donor pool 
expansion strategies such as the use of living donors, cadaveric split livers, and “extended 
criteria donors” (ECD)/marginal donors are being pursued. These may predispose recipients 
to graft dysfunction and increase long-term risk and survival in recipients. 
Primary graft non-function (PGNF) is the most severe type of graft damage after OLT, 
followed by initial poor graft function (IPGF) (Chui et al., 2000). Emergency hepatic 
retransplantation is necessary because of the extreme high mortality of PGNF. Evaluation of 
IPGF is determined by a high level of alanine aminotransferase (ALT) and/or aspartate 
aminotransferase (AST). IPGF directly influences the survival in the hepatic graft. 
Ultimately, some grafts recover completely while others need to be retransplanted (Pokorny 
et al., 2000). IPGF and PGNF are associated with many factors, such as status of donor, 
quality of hepatic graft, long-term warm ischemia, cold ischemia, primary liver disease, 
status of liver function of recipients and operative techniques (Brokelman et al., 1999). For 
evaluation of the donor hepatic allograft with regard to pre-existing diseases, in particular 
macrovesicular steatosis and post-transplant evaluation of hepatic graft function, liver 
biopsy is the most challenging and valuable clinical practice. Recently, some progress has 
been made in the prevention and treatment of early hepatic graft dysfunction. The present 
review provides broad discussion in the relevant sections. 
2. The definitions and clinical features 
2.1 Definitions of IPGF and PGNF 
The concept of primary graft dysfunction is not clear. In clinical liver transplantation, 
primary dysfunction is defined as IPGF or PGNF. The difference between IPGF and PGNF 
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considers the degree of dysfunction, the timing and length after liver transplantation and 
the need for urgent retransplantation.  
The diagnostic standard for IPGF has not been set yet, and there are different opinions 
among some reported definitions (Table 1). The criteria of Ploeg et al (Ploeg et al., 1993) and 
Gonzalez et al (Gonzalez et al., 1994) are adopted by some earlier studies. The introduction 
of Nanashima et al's criteria (Nanashima et al., 2002), which is simpler, more convenient and 
dependable, for an ALT and/or AST level above 1500 IU/L within 72 hours after OLT 
means poor hepatic allograft function as early as possible and also puts us on guard to 
prevent PGNF. 
 
Definitions of IPGF References 
Graded initial liver function (Gonzalez et al., 1994) 
Severe: sum of score 7-9  
Moderate:  5 or 6  
Mild:  3 or 4  
AST > 2000 IU/L and prothrombin time >16 s (Ploeg et al., 1994) 
on days 2-7  
ALT > 2500 IU/L within 3 days (Ardite et al., 1999) 
AST or ALT > 2500 IU/L within 24 hours (Chui et al., 2000) 
ALT or AST > 1500 IU/L within the first 3 days (Nanashima et al., 2002)  
Table 1. Diagnostic definitions of IPGF 
PGNF is manifested by hepatic cytolysis and rapidly rising transaminases, absence of bile 
production, severe liver-related coagulation deficit, hypoglycemia, high lactate levels, and 
hepatic hemodynamic instability (Uemura et al., 2007). According to the United Network for 
Organ Sharing (UNOS), PGNF is defined as irreversible graft function requiring emergency 
liver replacement during the first 10 days after liver transplantation. It is characterized by an 
AST ≥ 5000 UI/L, an international normalized ratio of prothrombin (INR) ≥ 3.0, and acidosis 
(pH ≤ 7.3 and/or lactate concentration ≥ 2× normal).  
Silberhumer et al (Silberhumer et al., 2007) proposed four grades of initial graft function 
over the first postoperative 5 days as: (1) good function, AST maximal 1000 UI/L and 
spontaneous prothrombin time > 50%; (2) fair function, AST 1000-2500 UI/L, clotting factor 
support < 2 days; (3) IPGF, AST > 2500 UI/L, clotting factor support > 2 days; and (4) PGNF, 
retransplantation required within 7 days.  
2.2 Clinical features 
IPGF is a severe clinical complication after OLT, with elevation of serum aminotransferase. 
Some patients may further develop PGNF (Mor et al., 1992), which is manifested by 
hepatocellular necrosis, rapidly rising transaminases, absence of bile production, severe 
liver-related coagulation deficit, high lactate levels, systemic hemodynamic instability and 
acute renal failure (Pokorny et al., 2000). 
Nevertheless, it is inconvenient to make the diagnosis of IPGF or PGNF due to the lack of 
precise to objective criteria in clinical practice. The great variability in the incidences 
reported in different series, which ranges from 2% and 23%. Ploeg et al reported the rates of 
IPGF and PGNF for 22% and 6%, respectively (Ploeg et al., 1993). Ardite et al's study 
showed the rates of IPGF and PGNF for 19% and 0% (Ardite et al., 1999) in contrast to 29.5% 
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and 0.93%, respectively in Chui et al's investigation (Chui et al., 2000). In the study by Chen 
et al, the rates of IPGF and PGNF were 36.25% and 1.3%, respectively (Chen et al., 2007). In 
The Scientific Registry for Transplant Recipients (SRTR) analysis enrolling 10545 deceased 
donors, adult first transplants, 613 (5.8%) cases of PNGF occurred (Johnson et al., 2007). In 
another single-center analysis of donors after cardiac death (DCD), PGNF occurred in 6.4% 
of brain dead donors (DBD) vs. 11.8% of DCD (Abt et al., 2004).  
In partial liver transplantation, the biochemical profile of small for-size syndrome (SFSS) 
includes cholestasis with elevated conjugated bilirubin, mild to moderate elevation of 
transaminases, and prolonged prothrombin time. Approximately 50% of recipients with 
SFSS will die of sepsis within 4 – 6 weeks after septicemia (Heaton, 2003). 
3. The impact of donor, recipient and factors associated with IPGF and PGNF 
Graft dysfunction can be a result of various factors including status of donor, quality of 
hepatic graft, organ harvesting, ischemia-reperfusion injury, SFSS, primary liver disease, 
status of liver function of recipients and operative techniques, etc. Although ECD from older 
donors or steatotic grafts provide a solution for the shortage of allografts, donor factors 
could still predispose recipients to IPGF and/or PGNF. With extended application of living 
donor liver transplantation (LDLT), SFSS has become the main problem. The occurrence of 
SFSS depends on a number of recipient, graft and technical factors. 
3.1 Recipient’ factors 
3.1.1 Child-Pugh classification and Model for End Stage Liver Disease (MELD) score 
In a retrospective study (Chen et al., 2007), Child-Pugh classification had no influence on the 
occurrence of IPGF, yet the ratio of Child-Pugh C in the IPGF group was higher than in the 
non-IPGF group. Their data suggested that Child-Pugh C of recipients was one possible risk 
factor leading to IPGF. 
The MELD score, which combines the serum creatinine, bilirubin, and INR of recipient to 
predict waitlist mortality, has been considered to be controversial in evaluating the 
occurrence of PGNF. In the SRTR analysis by Johnson et al, MELD score as a compound of 
risk factors was not included in models to predict PGNF (Johnson et al., 2007).  
Although MELD score at the time of transplantation showed only a trend of an association 
with recipient survival, it had no significant impact on initial graft function (Silberhumer et 
al., 2007). 
3.1.2 Other factors before transplantation 
Elderly recipient and urgent recipient status with the use of ECD graft were associated with 
an increased risk of death by 50% (Cameron et al., 2006). Although the recipient's age and 
clinical status before OLT were related to IPGF (Moreno Sanz et al., 1999), it was not 
confirmed in a recent study (Chen et al., 2007). In addition, the incidence of PGNF was more 
in male recipients receiving grafts from female donors than in patients with male donors 
(Marino et al., 1995). 
Avolio et al considered that hyperbilirubinemia before OLT was associated with PGNF 
(Avolio et al., 1999). In the STRT anslysis by Johnson et al, it was showed that by life 
support, mechanical ventilation, use of inotropes, hemodialysis, initial status 1 and use of a 
shared transplant were risk factors for PGNF by univariate analysis on recipients (Johnson 
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et al., 2007). In the multivariate model, only recipient serum creatinine, bilirubin, on life 
support and status 1 at transplant were significant risk factors for PGNF. For pediatric 
recipients, diagnosis of tumor, dialysis prior to transplant, recipient body weight ≤ 6 kg 
increased the risk of graft failure (Lee et al., 2008).  
Controversies exist regarding the morbidity and mortality of patients undergoing OLT at 
the extremes of the body mass index (BMI). An extremely BMI is defined as a BMI < 18.5 
kg/m2 or a BMI > 40 kg/m2. In a study of the UNOS database, which reviewed 73,538 adult 
liver transplants, there was no significant impact of underweight or very severely obese on 
the occurrence of PGNF though these patients experienced significantly higher rates of 
morbidity and mortality compared with recipients with intermediate BMI range (Dick et al., 
2009). 
3.2 Donor’s factors 
3.2.1 Extended criteria donors and marginal donors 
The use of ECDs is associated with increased graft loss and decreased survival. At present, 
no consensus has been reached for the definition of ECD graft. However, several risk factors 
associated with an increased rate of IPGF or PGNF have been identified. These risk factors 
include donor’s factors (age, gender, obesity, weight, height, BMI, elevated liver functions, 
hypotension/increased administration of vasopressor and hypernatremia, cause of donor 
death and graft steatosis) and transplant factors such as type of graft and cold ischemia time 
(CIT) (Müllhaupt et al., 2008).  
Definition for ECD by the suggestion of Chung et al includes age > 65 years, macrovesicular 
steatosis > 40%, serum sodium > 155 mmol/L, positive serological data, carcinoma outside 
the liver, DCD, and split-graft liver transplantation (Chung et al., 2010). In a large 
retrospective cohort study of 1153 OLT (Cameron et al., 2006), the ECD included donor age 
over 55 years, donor hospital stay >5 days, CIT >10 hours and warm ischemia time (WIT) > 
40 minutes. 
Marginal donors were considered by Pokorny et al as follows (Pokorny et al., 2005): older 
than 60 years, a prolonged intensive care unit (ICU) stay > 4 days with ventilatory support, 
a prolonged CIT >10 hours, a high vasopressor support (high-dose dopamine or any other 
vasoactive amines), a donor peak serum sodium > 155 mEq/L, a donor serum creatinine > 
1.2 mg/100 mL and BMI > 30. When patients had more than three cumulative marginal 
donor criteria, the rate of PGNF was 36% (Pokorny et al., 2005). 
3.2.2 Age 
Hepatic graft from old donor may increase susceptibility to cold ischemia-induced 
endothelial injury with impaired adenosine triphosphate (ATP) synthesis post reperfusion 
and result in decreased regenerative capacity and synthetic function (Gordon Burroughs & 
Busuttil, 2009). 
Donor age has been a well-recognized factor affecting PGNF. In the study by Feng et al, 
donor age over 40 years was associated significantly with the relative risk of graft failure 
(Feng et al., 2006). In the multivariate analysis by Lake et al, donor age over 40 was related 
with a 1.67 increased risk of graft failure in HCV-infected recipients and with 2.21 increased 
risk of graft failure when donor age was more than 60 years (Lake et al., 2005). In the SRTR 
analysis by Johnson et al, donor age more than 40 years was an independent factor for the 
prediction of PGNF (Johnson et al., 2007). Inversely, in other studies, donor age was not 
www.intechopen.com
Initial Poor Graft Dysfunction and Primary Graft  
Non-Function After Orthotopic Liver Transplantation 
 
187 
confirmed to increase the incidence of PGNF (Busquets et al.,2001; Grande et al.,1998; 
Washburn et al.,1996). However, these studies were based on a much smaller scale. 
3.2.3 Steatosis 
Hepatic steatosis is more common in donors of advanced age, as well as in those with a 
history of obesity, dyslipidemia, metabolic disorders, or diabetes.  
The decreased allograft survival rate after using fatty livers is seen in the early post-
transplant period (Verran et al., 2003). In contrast to macrovesicular steatosis, livers with 
predominantly microvesicular steatosis show less injury and allograft survival rates are 
similar to those in nonsteatotic grafts (Fishbein et al., 1997). So, adoption of an allograft with 
microvesicular steatosis is safe and the pool of donors has expanded. However, 
macrovesicular steatosis is one of the important risk factors leading to IPGF (Selzner & 
Clavien, 2001). Macrovesicular steatosis may impaire mitochondrial oxidation of fatty acids, 
increase synthesis and delivery of fatty acids to hepatocytes, reduce the removal of 
hepatocyte triglycerides, and microcirculatory disruption with narrowing of the hepatic 
sinusoids by enlarged, fat-laden hepatocytes (Reddy & Rao, 2006). Further more, 
macrovesicular steatosis may increase the oxidative injury of endothelial cell and hepatocyte 
and the vulnerability to secondary insults, including the cytokine surge associated with 
brain death as well as cold ischemic injury (Gordon Burroughs & Busuttil, 2009). In 
addition, the occurrence of IPGF or PGNF may be due to the release of free lipids from fatty 
hepatocytes, probably as a consequence of cold ischemia. Free lipids result in the production 
of reactive oxygen species after reperfusion initiating a cascade, which finally leads to 
sinusoidal endothelial cell damage (Selzner & Clavien, 2001; Kupiec-Weglinski & Busuttil, 
2005). Severe fatty livers are more susceptible to warm and cold ischemia reperfusion injury 
than normal ones (Kukan & Haddad, 2001). The type of damage is not through the pathway 
of cellular apoptosis, but necrosis (Selzner & Clavien, 2000). Overexpression of the 
mitochondrial uncoupling protein 2 in fatty livers may contribute to decreased cellular ATP 
levels (Serviddio et al., 2008), which reduces the capacity for hepatic regeneration (Selzner et 
al., 2000). There are some other factors which may play a role in fatty livers after 
reperfusion, like the down-regulation of peroxisome proliferator-activated receptor-ǂ, an 
important regulator of the hepatic inflammatory response to ischemia reperfusion, and 
overexpression of adiponectin, a fat cell-secreted hormone with antidiabetic and 
antiinflammatory activities (Massip-Salcedo et al., 2008). 
Ureña et al considered that hepatic allografts with moderate macrovesicular steatosis (30% – 
60%) can be used selectively in critical situations; mild macrovesicular steatosis (< 30%) is 
relatively safe, and severe cases (> 60%) enhance the rate of PGNF (Ureña et al., 1998; 
D'Alessandro et al., 1991). Canelo et al reported that PGNF can occur with donors having 
moderate macrovesicular steatosis. In this study, mild macrovesicular steatosis was 27.1% in 
the non-IPGF group and 13.8% in the IPGF group (Canelo et al., 2000). There was no 
significant difference between those groups.  
In the study by Verran et al, 6% of patients receiving grafts with severe macrovesicular fat 
required retransplantation within 3 months versus 1.4% of those receiving mildly steatotic 
grafts (Verran et al., 2003). In another multivariate analysis by Salizzoni et al, cumulative 
adverse factors on the incidence of PGNF included donor age, recipient HCV viremia, and 
prolonged CIT by use of grafts with over 15% macrovesicular steatosis (Salizzoni et al., 
2003). 
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3.3 Small-for-size syndrome (SFSS) 
SFSS is a well-recognized complication that occurs primarily in living donor or reduced 
size liver transplantation. The principal pathogenesis of SFSS is the unbalance between 
the accelerated liver regeneration and the increased demand of liver function, leading to 
severe graft dysfunction with prolonged hyperbilirubinemia and increased ascites 
(Ikegami et al., 2008). SFSS is caused by multiple factors including graft quality, recipient 
conditions and technique problems. SFSS is seen most frequently when the graft 
volume/standard liver volume ratio (GV/SLV) is less than 30% or partial liver grafts with 
graft weight/recipient weight ratios (GW/RW) less than 0.8%. Another important factor 
leading to SFSS is portal venous hypertension (Shimamura et al., 2001). In recent study by 
Hill et al, GW/RW did not appear to be the only determinant of outcome after partial 
liver transplantation and the occurrence of SFSS was influenced not only by the graft size 
but also by other factors such as the degree of portal hypertension as well (Hill et al., 
2009). For adult patient receiving right lobe graft, low intraoperative body temperature, 
graft size of < 35% of the estimated standard graft weight, and middle hepatic vein 
occlusion were significantly independent factors in determining hospital mortality (Fan et 
al., 2003). Other factors may impact the occurrence of SFSS (Emond et al., 1996; Yoshizumi 
et al., 2008): donor-related factors including advanced donor age and steatotic graft and 
recipient-related factors including higher MELD scores, septic complications, rejection 
and biliary complications. Donor age over 50 years is associated with reduced 
regenerative capacity, increased susceptibility to prolonged cold ischemia, increased rates 
of IPGF/PGNF and prolonged cholestasis. Fatty infiltration of 30% or more in grafts in 
splitting or auxiliary liver transplantation may increase incidence of SFSS (Heaton & Rela, 
2001).  
3.4 Ischemia reperfusion injury 
Hepatic ischemia reperfusion injury is an important factor related to IPGF (Mueller et al., 
1997). During the course of clinical liver transplantation, warm ischemia, cold ischemia, 
rewarming ischemia, and reperfusion occur sequentially in the allograft. Severe ischemia  
reperfusion injury leads to immediate graft non-function and triggers irreversible ischemic 
biliary lesions. 
3.4.1 Warm ischemia 
Hepatic warm ischemia occurs when the liver is maintained at body temperature but is 
inadequately perfused with blood. Although grafts from DCD increase the number of 
organs abailable, longer non-heart beating time and hypotension lead to warm ischemia, 
which may cause cell necrosis in the hepatic parenchyma after reperfusion and more easily 
result in IPGF or PGNF.  
The process of warm ischemia reperfusion injury involves activation of immune pathways 
and is dominated by hepatocellular injury. There are 2 distinct phases: the early phase (less 
than 2 hours after reperfusion) is marked by activation of immune cells (CD4+T cells and 
Kupffer cells) and production of oxidant stress; the later injury (6 to 48 hours after 
reperfusion) is characterized by neutrophil-mediated inflammation and hepatocellular 
injury (Klune & Tsung, 2010). In addition, warm ischemia also damages endothelial cells 
(Selzner et al., 2003; Teoh & Farrell, 2003). 
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As prolonged WIT is common with uncontrolled DCD, standardized criteria in donor 
selection have not been established and limited data concerning its use have been 
reported. D'Alessandro et al reported that the average WIT was 16.4 minutes in 19 cases of 
OLT using a DCD and the rate of PGNF was 10.5% (D'Alessandro et al., 2000). Gomez et 
al also reported that with 5-15 minutes average WIT, IPGF occurred in 6 of 8 cases and 
PGNF in the other two cases (Gomez et al., 1997). In a matched-pair analysis, PGNF was 
occurred 5.1% in livers of DCD versus 0% in those of DBD (Pine et al., 2009). In another 
retrospective study, PGNF was presented 3.7% in livers of DCD versus 1.4% in those of 
DBD (Grewal et al, 2009). In the study of 141 patients by de Vera et al, the incidence of 
PGNF was 12% in livers of DCD versus 3% in livers of DBD. WIT over 20 minutes was 
associated with poorer DCD outcomes (de Vera et al., 2009). In the study by Chen et al, 
the average WIT was significantly longer in the IPGF group than in the non-IPGF (Chen et 
al., 2007). Changes after warm ischemia were seen in liver biopsies before OLT. 
Furthermore, WIT was 7 minutes in only one case who suffered from PGNF. From logistic 
regression analysis, the possibility of IPGF was enhanced significantly when WIT 
exceeded 3 minutes. These results suggested that extension of WIT is a direct risk factor in 
bringing on IPGF. Recently, an analysis of OPTN/UNOS data demonstrates donor age > 
60 years, WIT > 30 minutes, CIT > 10 hours, retransplantation, and recipient 
cardiopulmonary support pre-OLT to be the most important predictors of significantly 
PGNF and patient survival after transplantation of a DCD graft (Mateo et al., 2006). 
Similarily, the University of California, Los Angeles (UCLA) reported with controlled 
DCD that PGNF occurred only in 2.6% of the recipients with about 30 minutes of mean 
WIT (Gordon Burroughs & Busuttil, 2009). 
3.4.2 Cold ischemia 
Although the cold preservation time of the allograft is extended greatly by the use of UW 
solution in clinical liver transplantation, cold ischemia is an important factor for IPGF and 
PGNF.  
Some investigations showed that sinusoidal endothelial cells are damaged first in cold 
ischemia reperfusion, then hepatocellular cells, because of activation of Kupffer cells and 
neutrophilic leukocytes, and the release of inflammatory mediators, which leads to 
impairment of hepatic allografts (Jaeschke, 2006). During the phase of cold ischemia, loss 
of mitochondrial respiration and ATP depletion occur consequently though hypothermia 
reduces the metabolic rate and prolongs the time that anoxic cells can retain essential 
metabolic functions (Selzner et al., 2003). Energy-dependent metabolic pathways and 
transport processes deteriorate and proteinases and metalloproteinases are activated. 
These changes lead to the sinusoidal endothelial cells to be lifted away from the 
underlying matrix. Loss of sinusoidal microvascular integrity and function that occurs 
during cold preservation is attributable to the reperfusion phase. The degree of 
endothelial damage has been correlated with functional impairment of the liver following 
reperfusion. 
Piratvisuth et al retrospectively summarized 230 cases of liver transplantation where the 
rate of IPGF was significantly higher when CIT was more than 720 minutes (Piratvisuth et 
al., 1995). In the study by Janny et al, AST level increased significantly after OLT if cold 
ischemia time was above 600 minutes (Janny et al., 1997). Adam et al thought that the 
possibility of hepatic allograft loss was significantly enhanced when cold ischemia time was 
www.intechopen.com
 
Liver Biopsy in Modern Medicine 
 
190 
over 720 minutes (Adam et al., 1992). De Vera et al suggested that CIT over 8 hours was 
significantly related to the occurence of PGNF (de Vera et al., 2009). In the study by Chen et 
al, the cold preservation time in all cases was within 1000 minutes, averaging 622 minutes in 
the IPGF group and 515 minutes in the non-IPGF group (Chen et al., 2007). A significant 
difference was shown by univariate analysis and not by multi-regression analysis. The 
results above suggested that extension of CIT is a potential risk factor for IPGF and PGNF. 
3.4.3 Rewarm ischemia 
The anhepatic phase was defined as the time from the physical removal of the liver from the 
recipient to the time of graft recirculation. During the anhepatic period, rewarming ischemia 
injury occurs because of the rise of allograft temperature. Strasberg et al considered that 
rewarming ischemia injury as the most important risk factor for IPGF can lead to increased 
AST level and decreased rate of allograft survival (Strasberg et al., 1994). The tolerance 
limits of allografts to rewarm ischemia time are not clear. In the study by Chen et al, 
although rewarming ischemia time was significantly longer in the IPGF group than in the 
non-IPGF group, shown by univariate ayalysis, multiregression analysis showed no 
significant difference between the two groups when rewarming ischemia time was above 45 
minutes (Chen et al., 2007). In Nanashima et al's investigation, average rewarming ischemia 
time was about 110 minutes in both IPGF group and non-IPGF group (Nanashima et al., 
2002). Platz et al reported that serum levels of ALT, AST, E-selectin and hyaluronic acid 
increased significantly if the anhepatic period was above 90 minutes (Platz et al., 1997). 
Delva et al thought that rewarm ischemia time should not exceed 60 minutes (Delva et al., 
1989). Recently, in a logistic regression analysis by Ijtsma et al, the anhepatic phase over 100 
minutes [odds ratio (OR), 4.28] was an independent predictive factor for graft dysfunction 
(Ijtsma et al., 2009). These results suggested that extended rewarming ischemia time is an 
important risk factor for IPGF. 
4. Histopathological characteristics 
For evaluation of the donor hepatic allograft with regard to pre-existing diseases, in 
particular macrovesicular steatosis and post-transplant evaluation of hepatic graft function, 
liver biopsy is the most challenging and valuable clinical practice. 
4.1 Steatosis of donors 
Excessively fatty liver, specifically macrovesicular (large droplet) fatty liver, is associated 
closely with risk for IPGF or PGNF. Microvesicular (small droplet) fat in the donor liver is 
not a contraindication for transplantation (Fishbein et al., 1997). As macroscopy is unreliable 
in the appraisal of the severity of steatosis, bioptical evaluation before transplantation is 
recommended in cases where significant steatosis is suspected. The percentage of steatosis 
should be determined by liver biopsy before transplantation.  
4.2 Ischemia reperfusion injury 
According to the experiences of Demetris et al, it is electron microscopy, not light 
microscopic examination, before transplantation which can be used to accurately assess the 
cold ischemia injury and post-transplant allograft function (Demetris et al., 2009). However, 
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after reperfusion, light microscopic examination is more informative. Reperfusion biopsies 
show the damage, with reasonable accuracy, can predict IPGF or PGNF during the first few 
weeks post operation. 
Severe cold preservation reperfusion damage is one of the major reasons for PGNF. 
Histologically, it is characterized by massive necrosis, which becomes evident within the 
first 48 hours after transplantation (Chazouillères et al., 1993). The hepatic 
microenvironment involving in the pathogenesis of preservation injury includes 
lymphocytes, hepatocytes, bile duct epithelium, sinusoidal cells, Kupffer cells, neutrophilic 
leukocytes and platelets. Sinusoidal endothelial cells are the first affected then hepatic 
parenchymal cells (Clavien, 1998) and finally hepatic allograft function is impaired. 
Most biopsy specimens were essentially normal before transplantation except for focal mild 
spotty acidophilic necrosis, a slight increase in sinusoidal inflammatory cells and mild 
hepatocellular swelling. It is important that the integrity of the sinusoidal lining cells could 
not be evaluated reliably with immersion fixed, paraffin-embedded and hematoxylin and 
eosin-stained slides of biopsy specimens before transplantation. By contrast to biopsy 
specimens before transplantation, various pathological findings after reperfusion are 
demonstrated. In severe cold ischemia reperfusion injury under the examination of light 
microscopy (Kakizoe et al., 1990), larger areas of necrosis appeared, which were classified as 
focal or zonal with periportal or bridging necrosis, and severe neutrophilic exudation. The 
focal or zonal necrosis was either centrilobular, periportal, or both in its distribution. In 
general, the degree of inflammation increased after revascularization and paralleled the 
degree of necrosis. For hepatocytes, microvesicular steatosis, focal hepatocellular 
cytoaggregation and mild hydropic cell swelling were detected. In more severe injury, if 
hepatocellular necrosis was mainly in zone 3, centrilobular hepatocyte dropout is seen. The 
adjacent viable zone 2 hepatocytes proliferate to restore the liver parenchyma, and mitoses 
are seen. If periportal necrosis and bridging necrosis are present, the parenchymal collapse 
triggers ductular reaction that can link adjacent portal tracts and distort the architecture. 
More severe injury is also usually accompanied by centrilobular hepatocellular swelling, 
and canalicular and cholangiolar cholestasis (Demetris et al., 1987).  
Ultrastructural analysis by Kakizoe et al revealed that the sinusoidal microvasculature was 
more sensitive to organ procurement and cold preservation than the endothelium of larger 
vessels or hepatocytes (Kakizoe et al., 1990). These changes at the end of cold ischemia 
before transplantation included endothelial cell vacuolization and a partial or complete 
detachment of individual cells, resulting in denudation with loss of the space of Disse. The 
sinusoids contained cellular debris, presumably fragments of hepatocytes, detached 
endothelial cells and occasional inflammatory cells. The hepatocellular changes detected 
were relatively mild and included cytoplasmic fat vacuolization, a decrease in the 
mitochondrial matrix, formation of hepatocellular cytoplasmic blebs protruding into the 
sinusoids and occasional loss of hepatocyte microvilli on the sinusoidal surface. After 
reperfusion, increased sinusoidal cellular debris, focal sinusoidal endothelial cell 
denudation and occasional active appearing Kupffer cells that contained cytoplasmic 
vacuoles and electron-dense material are observed. Inflammatory cells were often clustered 
in areas of microarchitectural distortion and sinusoidal lining cell denudation. They were 
also seen near Kupffer cells and directly adherent to hepatocytes or amidst cellular debris. 
Hepatocyte alterations were relatively mild. The changes included an increase in lipid 
vacuolization, detachment of cytoplasmic blebs and, in some areas, formation of 
electrondense material in the cytoplasm. The mitochondria in some cases showed mild 
www.intechopen.com
 
Liver Biopsy in Modern Medicine 
 
192 
swelling, and the rough endoplasmic reticulum showed focal mild fusiform dilatation when 
compared with samples taken before transplantation.  
In some circumstances, the histological findings showed minimal alterations in some 
patients who experienced IPGF or PGNF. Biopsies after reperfusion may be performed too 
soon after reperfusion to detect morphological changes of irreversible ischemic injury. 
4.3 SFSS 
The histopathologic features of SFSS had been summarized by Demetris et al (Demetris et 
al., 2006). The portal vein and sinusoidal injury could be divided into early, intermediate, 
and late changes. Early changes include focal endothelial denudation that is accompanied 
by hemorrhage into the portal connective tissue that occasionally dissects deeper into the 
hepatic parenchyma when it is severe. Denudation of portal vein and periportal sinusoidal 
endothelium, severe congestion with frank rupture and thrombosis of the periportal 
sinusoids may occur as early as 5 minutes after transplantation in grafts of less than 30% 
expected liver volume (Kelly et al., 2004). Intermediate and late portal venous changes are 
associated with repair of the early changes. Endothelial cell hypertrophy, subendothelial 
edema accompanied by an in-growth of myofibroblasts and endothelial cells resulting in 
focal fibrosis, and luminal obliteration or recanalization of thrombi may be present. 
In addition, functional dearterialization could be observed because of arterial vasospasm 
and/or arterial thrombosis. The arterial lesions are invariably accompanied by large 
perihilar bile duct necrosis, cholangitic abscesses, leakage of bile in the surrounding 
connective tissue, and scattered parenchymal infarcts. The most characteristic triad of 
histopathologic findings present include centrilobular hepatocanalicular cholestasis, 
centrilobular hepatocyte microvesicular steatosis, and a low-grade ductular reaction at the 
interface zone. The ductular reaction consisted of portal tract expansion because of an 
increase of ductal profiles at the interface zone accompanied by acute neutrophilic 
periductular inflammation. 
Based on the above pathological manifestations, Demetris et al proposed the following 
sequence of SFSS (Demetris et al., 2006). First, portal venous hyperperfusion causes portal vein 
and sinusoidal endothelial cell injury which leads to intraparenchymal dissecting hemorrhage 
in severe cases. Second, portal hyperperfusion triggers the arterial buffer response (Marcos et 
al., 2000), hepatic arterial vasospasm, and decreased hepatic artery perfusion. Decreased 
hepatic arterial blood flow can also be presented in most reduced-size liver allografts (Marcos 
et al., 2000). Third, centrilobular microvesicular steatosis and infarcts in the periphery are 
caused by poor arterial flow and ischemia. In the hilum, it manifests as ischemic cholangitis in 
severe cases (Ludwig et al., 1992). Last, remnants of portal vein pathology often cause 
organizing mural thrombi or thickening in large branches portal vein branches and partial or 
complete luminal obliteration or recanalization in small portal vein branches. 
However, the histopathologic and pathophysiologic manifestations of SFSS have not been 
depended completely on peripheral core needle biopsies (Demetris et al., 2006). Under the 
examination of peripheral core needle biopsies, affected grafts most commonly show the 
following triad: centrilobular hepatocanalicular cholestasis, centrilobular hepatocyte 
microvesicular steatosis, and a ductular reaction at the interface zone. Venous pathology 
could not be detected by peripheral core needle biopsies in failed allograft though the 
presentation of venous changes is particularly helpful for the diagnosis of SFSS. In addition, 
it should be kept in mind that the changes in zone 3 and ductular reaction are not specific 
for SFSS. The detection should include suboptimal arterial flow as hepatic artery thrombosis 
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or bile duct stricturing are not related to the SFSS, and systemic causes such as sepsis with 
or without systemic hypotension. 
5. The strategy for prevention and treatment 
As PGNF is the most severe type of IPGF and a life threatening condition, there is growing 
need for early identification of IPGF and PGNF. This may help to determine further 
therapeutic interventions, changes in therapeutic protocols or additional diagnostic 
procedures aiming at preventing IPGF and PGNF.  
5.1 Early diagnosis 
At present, confirmation of IPGF and PGNF still depends on daily monitoring of liver 
function, renal function, blood coagulation function, hemodynamic and respiratory 
parameters, as well as liver biopsy. In order to reach a quick and accurate diagnosis, it 
requires careful interpretation of allograft biopsy and correlation of hepatic 
histopathological characteristics with clinical and laboratory findings. As laboratory tests 
may reflect later results of IPGF or PGNF, early biomarkers should be searched.  
Recently, Dahaba et al assessed Bispectral index (BIS) monitoring as an early intraoperative 
indicator of living-donor or DCD graft function (Dahaba et al., 2009). BIS monitoring, an 
electroencephalographic (EEG)-derived parameter, is a useful measure for grading and 
monitoring the degree of central nervous system involvement in patients with chronic liver 
disease. BIS increase was associated significantly with non-IPGF but not with the occurrence 
of IPGF, which indicates predictive power of BIS monitoring as an indicator of the return of 
cerebral activity with the restoration of graft hepatic function.  
In animal model of liver transplantation by using non-heart beating donor, the levels of 
serum ǃ-galactosidase, IL-6, hyaluronic acid and redox-activate iron are closely associated 
with early confirmation of IPGF and PGNF (Monbaliu et al., 2007). 
5.2 Donor-recipient matching models 
As various donor and recipient risk factors influence graft function and survival after OLT 
(see Table 2), identifying the right set of donor and recipient matching characteristics may be 
very important, especially in the face of increasing use of DCD.  
From the data of SRTR, Feng et al identified seven donor characteristics that be 
independently used to predict significantly increased risk of graft failure and developed a 
quantitative donor risk index (DRI) using Cox regression models (Feng et al., 2006). By 
using DRI, the risk of donor liver graft could be assessed quantitatively. In another large 
analysis by using the data from the UNOS of 20,301 recipients, a comprehensive model that 
predicts survival after liver transplantation was developed and validated based on donor 
and recipient characteristics (Ioannou, 2006). These models could adequately predict 
survival after OLT in patients with or without hepatitis C virus and have a large effect on 
post-transplant survival. 
By using the OPTN/SRTR data base on 21673 liver transplant recipients, Rana et al  
identified 13 recipient factors, 4 donor factors and 2 operative factors (warm and cold 
ischemia) as significant predictors of recipient mortality (Rana et al., 2008). The multivariate 
analysis in this study included all of the variables considered in the SRTR risk-adjusted 
model. The Survival Outcomes Following Liver Transplant (SOFT) score was evaluated by 
utilizing 18 risk factors to successfully predict 3-month recipient survival following liver 
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transplantation. Furthermore, the proposed SOFT risk score can be used to predict outcomes 
for a particular recipient and donor allograft prior to transplantation comparing against 
waitlist mortality predicted by the MELD score. However, the SOFT score addresses only 3-
month mortality comparing other studies which look at longerterm outcome. 
 
Study Markmann Cuende Busuttil Feng Ioannou Rana 
References (Markmann 
et al., 2001) 
(Cuende  
et al., 2005)
(Busuttil  
et al., 2005)
(Feng  
et al., 2006)
(Ioannou 
et al., 2006) 
(Rana  
et al., 2008) 
Number in study 1393 5150 3200 20023 38811 21673 
Year range of data 1992 - 1998 1994 - 2110 1984 - 2001 1998 - 2002 1994 - 2003 2002 - 2006 
Data source UCLA Spain UCLA SRTR UNOS UNOS 
Donor factors       
    Age       
    Race       
    Gender       
    Height       
    Hypertension       
    Cause of donor  
death 
      
    DCD       
    Length of donor 
hospital/ICU stay 
      
    Serum sodium level       
    Serum bicarbonate 
level 
      
    Serum creatinine 
level 
      
Recipient factors       
    Age       
    Recipient urgency       
    Preoperative 
mechanical ventilation
      
    Serum creatinine 
level 
      
    Serum albumin level       
    Cause of recipient's 
liver disease 
      
    Retransplantation       
    BMI       
    MELD score       
Transplant factors       
    Warm ischemia time       
    Cold ischemia time       
    Partial- or split-liver 
graft 
      
Table 2. Factors effecting graft function or graft survival 
Given the importance of advanced donor age and graft quality, Halldorson et al developed 
a statistic, D-MELD, the product of donor age and preoperative MELD, calculated from 
laboratory values (Halldorson et al., 2009). Using a cutoff D-MELD score of 1600, they 
defined a subgroup of donor-recipient matches with significantly poorer short- and long-
term outcomes as measured by survival and length of stay. It can be used to accurately 
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estimate the risk for various donor/recipient combinations and predicte worse outcome in 
recipients after OLT if D-MELD ≥ 1600. In an observational cohort study that prospectively 
enrolled liver transplantations performed at 20 out of 21 Italian Transplant Centres, it was 
demonstrated that the liver donor population used for transplantation in Italy has a higher 
risk profile mainly because of older donor age (Angelico et al., 2011). 
The models above are aimed to help clinicians balance waitlist mortality with posttransplant 
outcome and make right decisions on a particular allograft. Freeman (Freeman, 2008) 
suggested that the differences between statistical calculations and decision made for 
individual patients with various treatment options should be emphasized though these 
models have some useful information for donor-recipient matching. 
5.3 Prevention and treatment 
5.3.1 General consideration 
Recently, some progress has been made in the prevention and treatment of early hepatic 
graft dysfunction. In the clinical practice, limitation of the use of liver grafts from patients 
older than 50 years should be complied. For steatotic donor grafts, restricting the use of 
steatotic livers to those with less than 40% macrovesicular steatosis is recommended. Livers 
with large droplet fat in excess of 60% are at increased risk for primary graft 
dysfunction/nonfunction and are therefore typically excluded from transplantation 
(Trevisani et al., 1996/Ploeg et al., 1993). As with other ECD grafts, recipient matching 
should be based on the number and extent of recipient risk factors and the absence of other 
negative donor variables, such as advanced donor age and prolonged CIT, to minimize the 
negative impact on graft and patient’s outcome. Determination of the BMI seems to be a 
helpful and non-invasive method to estimate the degree of liver steatosis, particularly in 
living donors (Rinella et al., 2001; Trotter, 2001). Individuals with normal BMI usually do 
not have steatosis (Rinella et al., 2001).  
5.3.2 Surgical strategies 
For reduction of severe ischemia reperfusion injury of graft, surgical strategies have been 
undertaken. It is recommended that the time from pronouncement of cardiac death until 
liver perfusion with preservation solution and CIT should be between 20 minutes to 12 
hours. For the use of uncontrolled non-heart-beating donors, normothermic extracorporeal 
membrane oxygenation (NECMO) were adopted in a prospective case-control study on 
adult patients undergoing OLT, and the results are encouraging (Jiménez-Galanes et al., 
2009). Prior to major hepatectomy, ischemic preconditioning (IP) of the liver has been 
successfully employed to protect against subsequent prolonged periods of ischemia (Clavien 
et al., 2000). The aim of IP is to induce resistance to a subsequent longer episode of ischemia 
by a short episode of ischemia reperfusion. The development of hepatic preconditioning can 
be differentiated into 2 phases. An early phase of protection occurs immediately after IP. 
The subsequent phase (late preconditioning) begins 12-24 hours after the stimulus and the 
induction of cytoprotective genes, including HSP70, HSP27, and HSP32/heme oxygenase 1. 
Hepatic preconditioning is not limited to parenchymal cells but also ameliorates sinusoidal 
perfusion, prevents postischemic Kupffer cell activation, neutrophil infiltration, and 
decreases the production of proinflammatory cytokines, oxidative injury and apoptosis 
(Carini & Albano, 2003). In a prospective randomized study on 100 patients undergoing 
major liver resection to the impact of ischemic preconditioning was evaluated (Clavien et al., 
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2003). Postoperative serum transaminase levels were significantly lower in preconditioned 
group than in control group, with even more benefits in younger patients, longer duration 
of inflow occlusion, where resected volume <50%, and in the presence of steatosis (Clavien 
et al., 2003). Recently in experimental settings, graft preservation by normothermic machine 
perfusion has proven superiority over static cold storage. Normothermic perfusion could 
preserve extended criteria grafts for long periods, assess the viability of these grafts during 
perfusion and improve the condition of the grafts (Vogel et al., 2010). However, the 
feasibility and the device of the normothermic machine perfusion should be introduced and 
evaluated in human livers.  
5.3.3 Pharmacological strategies 
Pharmacological treatments include (Bahde & Spiegel, 2010): first, antioxidant therapy 
aiming at supporting endogenous antioxidants and inhibiting ROS generation; second, 
vasoactive mediators, such as ET, angiotensin II, thromboxane A2, NO, carbon monoxide, 
prostaglandin E1 and prostacyclin, can ameliorate the hepatic microcirculation; third, anti-
inflammatory drugs in order to reduce ischemia reperfusion injury via selectin, cyclo-
oxygenase 2 and protease inhibition, cytokines (including TNF-ǂ and IL-1) and chemokine 
blockade; fourth, antiapoptotic strategies, including mitochondrial permeability transition 
inhibitors (ciclosporin A, trifluoperazine), anti-Fas or anti-Fas ligand antibodies, 
antiapoptotic proteins, caspase inhibitors and others; fifth, pharmacological preconditioning 
imitating the protective mechanisms induced by IP; finally, glucose infusion, by supplying 
glucose for ATP generation. A total of 14 RCTs were identified for evaluating these 
pharmacological measurements. Although some pharmacological strategies showed 
promising results with improved hepatic function and clinical outcome, but there is still not 
solid evidence to recommend its application in clinical. However, methylprednisolone 
(Aldrighetti et al., 2006; Pulitanò et al., 2007) and sevoflurane (Beck-Schimmer et al., 2008) 
are the most promising drugs for reduction of ischemia reperfusion injury. 
5.3.4 SPSS 
For prevention of SFSS in partial liver transplantation, several interventions should be 
considered. First, selection of grafts from healthy donors without advanced age. Second, 
graft steatosis of 30% or more should preclude. Third, sufficient graft volume should be 
guaranteed. In the pediatric population, the recipient receives an adult lateral left segment 
or left lobe. In adult-to-adult LDLT, an extended right lobe graft with or without middle 
hepatic vein can increase graft volume though the donor is relatively small (Lo et al., 2004; 
Cattral et al., 2004). Finally, ischemic preconditioning may also be of benefit in partial liver 
transplantation to protect SFSS grafts, as it has been shown to maintain the hepatic 
microcirculation and decrease the activation of Kupffer cells (Franco-Gou et al., 2004; 
Vajdová et al., 2004). 
5.3.5 Retransplantation 
Early retransplantation is the only choice of treatment in patients with PGNF. It was 
reported by Grande et al that the third postoperative day is a crucial time in making the 
decision of retransplantation in patients with IPGF (Grande et al., 1992). It is because that 
the improvement of liver function began on the third day in almost all patients whose graft 
dysfunction spontaneously ameliorated. Upon the diagnosis of PGNF, rescue hepatectomy 
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of the non-functioning liver can achieve a dramatic temporary clinical improvement as 
failing graft causes the pathophysiology of this disorder and extrahepatic sequelae. 
Retransplant after PGNF in the initial transplant can achieve relatively good long-term 
survival (Uemura et al., 2007). However, a second or third transplant after PGNF did not 
demonstrate long-term survival, and hospital mortality was 57% (Uemura et al., 2007). In 
addition, the patient’s and graft’s survival were lower in recipients with hepatitis C virus 
infection who received retransplantation when compared with those without HCV infection 
as HCV was an independent predictor of mortality after retransplantation (Yoo et al., 2003). 
6. Conclusion 
IPGF is a severe complication after OLT while PGNF is a life-threatening event. The factors 
of donor, recipient and operation contribute to the occurrences of IPGF or PGNF. For 
evaluation of the donor hepatic allograft and post-transplant evaluation of hepatic graft 
function, liver biopsy as well as with clinical and laboratory findings are important for early 
diagnosis in clinical practice. For prevention of IPGF or PGNF, it is necessary for careful 
consideration of donor and recipient factors before OLT. Surgical and pharmacological 
interventions should be undertaken cautiously. 
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